Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Glucagon-Like Peptide-1 Receptor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT06282458
What this trial is testing

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Who this might be right for
Muscle LossObesity
Veru Inc. 168
Not applicableLooking for participantsNCT07702461
What this trial is testing

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

Who this might be right for
Obesity & OverweightDiabetes (DM)
Ohio State University 300
Not applicableUnknownNCT04383197
What this trial is testing

Exercise and GLP-1 RA on Insulin Secretion

Who this might be right for
Type 2 Diabetes
University of Copenhagen 30
Not applicableUnknownNCT04733508
What this trial is testing

Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes

Who this might be right for
Diabetes MellitusDiabetes Mellitus, Type 2
Radboud University Medical Center 28
Not applicableLooking for participantsNCT07244458
What this trial is testing

Dietary Peanuts and Nutrition-Related Outcomes

Who this might be right for
Dietary ChangeObesity & OverweightFood Acceptance
Ian J. Neeland, MD 64
Large-scale testing (Phase 3)Looking for participantsNCT07575399
What this trial is testing

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Who this might be right for
Obesity or Overweight
Amgen 300
Large-scale testing (Phase 3)Study completedNCT03954834
What this trial is testing

Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Who this might be right for
Type 2 Diabetes Mellitus
Eli Lilly and Company 478
Testing effectiveness (Phase 2)Study completedNCT03712098
What this trial is testing

Daily Liraglutide for Nicotine Dependence

Who this might be right for
Smoking CessationWeight, Body
Rebecca Ashare 40
Post-approval studies (Phase 4)Study completedNCT05786521
What this trial is testing

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Who this might be right for
AgingDiabetes Mellitus, Type 2PreDiabetes+1 more
The University of Texas Health Science Center at San Antonio 20
Post-approval studies (Phase 4)Looking for participantsNCT07777575
What this trial is testing

Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

Who this might be right for
Obesity (BMI>30)
Technical University of Munich 150
Post-approval studies (Phase 4)UnknownNCT02501850
What this trial is testing

The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

Who this might be right for
Diabetes Mellitus Type 2
Hospital Universitari Vall d'Hebron Research Institute 40
Not applicableLooking for participantsNCT06271200
What this trial is testing

Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)

Who this might be right for
Metabolic Syndrome
National Health Research Institutes, Taiwan 200
Testing effectiveness (Phase 2)Looking for participantsNCT07221214
What this trial is testing

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

Who this might be right for
HIVAlcoholSmoking Cigarette+1 more
Vanderbilt University Medical Center 200
Very early researchUnknownNCT02560376
What this trial is testing

68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

Who this might be right for
InsulinomaNesidioblastosis
Peking Union Medical College Hospital 100
Not applicableLooking for participantsNCT07495904
What this trial is testing

Effect of GLP-1 Receptor Agonists on Body Composition in Obesity: The Role of Dietary Protein Consumption in Muscle Mass Maintenance

Who this might be right for
Obesity
Hellenic Mediterranean University 130
Testing effectiveness (Phase 2)Study completedNCT06901648
What this trial is testing

HS-20094 in Patients With T2DM

Who this might be right for
Type 2 Diabetes
Jiangsu Hansoh Pharmaceutical Co., Ltd. 275
Large-scale testing (Phase 3)Study completedNCT02042664
What this trial is testing

Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

Who this might be right for
ObesityDiabetes
Assistance Publique Hopitaux De Marseille 44
Post-approval studies (Phase 4)Study completedNCT04781998
What this trial is testing

Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?

Who this might be right for
Mental DisorderMetabolic DisturbanceFeasibility+2 more
Anders Fink-Jensen, MD, DMSci 24
Testing effectiveness (Phase 2)Looking for participantsNCT07107334
What this trial is testing

Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

Who this might be right for
Endometrioid Endometrial Adenocarcinoma
University of Florida 20
Early research (Phase 1)Ended earlyNCT05762744
What this trial is testing

Pharmacogenomics of GLP1 Receptor Agonists

Who this might be right for
Type 2 Diabetes
University of Maryland, Baltimore 63
Next Page